Concepedia

Author

Juliette Foucher

Inserm

Also Known As

Foucher, Juliette, J FOUCHER, J Foucher, J. Foucher, Juliette Foucher, Philippe Sogni, Victor de Ledinghen

50

Publications

698

Citations

11

H-Index

29

Concepts

All Affiliations

InsermHôpital Cardiologique du Haut-LévêqueSorbonne UniversitéCentre Hospitalier Universitaire de BordeauxHôpital Saint Joseph
JF

About

Juliette Foucher is an author at Inserm specializing in hepatitis, viral hepatitis, and medicine.

Top Concepts

#ConceptH-IndexPublicationsCitations

1

Medicine

6

6

333

2

Hepatology

4

4

277

3

Public Health

2

2

56

4

Epidemiology

2

2

56

5

Health Policy

1

1

40

Juliette Foucher

×

10

Publications

594

Citations

10

H-Index

YearCitations

Effect of Ribavirin in Genotype 1 Patients With Hepatitis C Responding to Pegylated Interferon Alfa-2a Plus Ribavirin

Jean–Pierre Bronowicki, Denis Ouzan, Tarik Asselah,

Gastroenterology

2006

183

Non‐invasive tests for fibrosis and liver stiffness predict 5‐year survival of patients chronically infected with hepatitis B virus

Victor de Lédinghen, J. Vergniol, Christine Barthe,

Alimentary Pharmacology & Therapeutics

2013

108

Transient elastography and biomarkers for liver fibrosis assessment and follow-up of inactive hepatitis B carriers

Laurent Castéra, Pierre–Henri Bernard, Brigitte Le Bail,

Alimentary Pharmacology & Therapeutics

2011

85

Influence of the HCV subtype on the virological response to pegylated interferon and ribavirin therapy

Florence Abravanel, Philippe Colson, Hélène Leguillou‐Guillemette,

Journal of Medical Virology

2009

58

Staging chronic hepatitis B into seven categories, defining inactive carriers and assessing treatment impact using a fibrosis biomarker (FibroTest®) and elastography (FibroScan®)

Thierry Poynard, Julien Vergniol, Yen Ngo,

Journal of Hepatology

2014

46

Hepatitis C virus prevention and care for drug injectors: the French approach

Jean‐Michel Delile, Victor de Lédinghen, Marie Jauffret‐Roustide,

Hepatology Medicine and Policy

2018

40

High-Dose Pegylated Interferon-α and Ribavirin in Nonresponder Hepatitis C Patients and Relationship With IL-28B Genotype (SYREN Trial)

Stéphane Chevaliez, Christophe Hézode, Alexandre Soulier,

Gastroenterology

2011

27

Daily or three times a week interferon alfa-2b in combination with ribavirin or interferon alone for the treatment of patients with chronic hepatitis C

Victor de Lédinghen, Pascale Trimoulet, María Winnock,

Journal of Hepatology

2002

21

Evolutionary history of hepatitis C virus genotype 5a in France, a multicenter ANRS study

Cécile Henquell, Julien Guglielmini, Jannick Verbeeck,

Infection Genetics and Evolution

2011

16

Neutralizing antibodies to interferon‐α and circulating interferon in patients with chronic hepatitis C non‐responding to pegylated interferon plus ribavirin re‐treated by pegylated interferon‐α‐2a and ribavirin (ANRS HC16 GAMMATRI substudy*)

Philippe Halfon, Sophie Pérusat, Marc Bourlière,

Journal of Medical Virology

2010

10

Page 1